Why is this medication prescribed?

Imlygic is a prescription medication that is used for the treatment of certain types of skin cancer. Specifically, it is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Imlygic is a modified form of the herpes simplex virus type 1 (HSV-1) that has been engineered to selectively replicate within tumor cells and produce an immune response against the cancer. It works by directly infecting and killing tumor cells, as well as stimulating an immune response that can target and destroy cancer cells throughout the body.

How should this medicine be used?

Imlygic (talimogene laherparepvec) is a prescription medication used for the treatment of certain types of skin cancer. It is administered through injections directly into the skin lesion(s) or surrounding tissue. Here is a general overview of how Imlygic should be used:

• Administration by healthcare professional: Imlygic injections are typically given by a healthcare professional in a clinic or hospital setting. The healthcare professional will have experience in the management of cancer therapies and will be responsible for administering the medication.
• Treatment schedule: The treatment schedule for Imlygic may vary depending on the individual patient and the extent of the disease. The healthcare professional will determine the appropriate treatment plan based on the specific circumstances. Generally, the initial treatment phase is followed by additional treatments at specific intervals.
• Preparation: Imlygic is supplied as a suspension and needs to be prepared before administration. The healthcare professional will follow the appropriate instructions provided by the manufacturer for reconstitution and preparation of the medication.
• Injection technique: The healthcare professional will use sterile techniques to administer Imlygic injections. They will identify the lesion(s) or target area and inject the medication directly into the tumor or surrounding tissue. The exact injection technique may vary depending on the location and size of the lesion.
• Monitoring and follow-up: After the administration of Imlygic, the healthcare professional will monitor the patient for any potential side effects or adverse reactions. They will also provide instructions on post-treatment care and follow-up visits.

It’s important to note that the specific dosage, treatment schedule, and administration technique for Imlygic will be determined by the healthcare professional based on the individual patient’s condition. Patients should always follow the instructions provided by their healthcare provider and seek clarification for any questions or concerns they may have regarding the use of Imlygic.

Other uses for this medicine

Imlygic (talimogene laherparepvec) is primarily indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. However, it is important to note that Imlygic is not approved for the treatment of other types of cancer or conditions. Its use should be limited to the specific indication as determined by a healthcare professional.

What special precautions should I follow?

Regarding special precautions for Imlygic, here are some important considerations:

• Allergic reactions: Individuals who are allergic to any components of Imlygic should not receive the medication. It is essential to inform the healthcare professional about any known allergies before starting treatment.
• Infection control: Imlygic is a modified herpes simplex virus type 1 (HSV-1). During and after treatment, patients should take precautions to avoid direct contact between the injection site(s) and mucosal surfaces, such as the eyes and genitals, as this can result in herpes infection.
• Immune system interactions: Imlygic may interact with the immune system, leading to immune-related adverse events. Patients with compromised immune systems or those taking immunosuppressive medications should use caution when considering Imlygic treatment.
• Potential for transmission: Imlygic contains a live virus that may be shed from the injection site(s). Precautions should be taken to prevent potential transmission to others, including avoiding close contact with individuals who have weakened immune systems, such as those who are pregnant or have received an organ transplant.
• Adverse reactions: Common side effects of Imlygic include flu-like symptoms, fatigue, nausea, injection site reactions, and fever. It is important to report any unexpected or severe side effects to a healthcare professional.
• Pregnancy and breastfeeding: The use of Imlygic during pregnancy or breastfeeding has not been adequately studied. It is essential to discuss the potential risks and benefits with a healthcare professional if you are pregnant or breastfeeding.

As with any medication, it is crucial to consult with a healthcare professional before starting Imlygic to fully understand the potential risks and benefits, as well as to discuss any specific precautions or concerns related to your individual health condition.

What special dietary instructions should I follow?

There are no specific dietary restrictions associated with Imlygic. You can typically follow your normal diet while taking this medication. However, it’s always a good idea to maintain a healthy and balanced diet to support your overall well-being and immune system.

What should I do if I forget a dose?

If you forget a dose of Imlygic, it’s important to contact your healthcare provider for guidance. They will provide you with specific instructions on what to do in such situations. It is generally not recommended to administer an extra dose to make up for the missed one without consulting your healthcare provider first.

What side effects can this medication cause?

Like any medication, Imlygic may cause side effects. Some common side effects of Imlygic include:

• Flu-like symptoms: These may include fever, chills, fatigue, muscle aches, and headache.
• Injection site reactions: Imlygic is injected directly into the melanoma lesions, and it can cause pain, swelling, redness, itching, bruising, and bleeding at the injection site. Some people may develop skin ulcers or infections at the injection site.
• Fatigue: Feeling tired or weak is a common side effect of Imlygic treatment.
• Nausea: Some individuals may experience nausea or vomiting after receiving Imlygic injections.
• Fever: Imlygic can cause an increase in body temperature.
• Pain: Patients may experience general discomfort or pain in the treated area.
• Cellulitis: Cellulitis is a bacterial infection of the skin and tissue beneath the skin. It can occur at the injection site or in nearby areas.

It’s important to note that not everyone will experience these side effects, and their severity can vary from person to person. It’s essential to discuss any concerns or potential side effects with your healthcare provider before starting Imlygic treatment. They can provide more personalized information and guidance based on your specific situation.

What should I know about storage and disposal of this medication?

• Storage: Imlygic should be stored in a refrigerator between 2°C and 8°C (36°F and 46°F). Do not freeze the medication. Keep it in the original carton to protect it from light until ready for use.
• Disposal: Any unused or expired Imlygic vials should be disposed of properly. It is recommended to consult your healthcare provider, pharmacist, or local waste disposal authority for specific instructions on the appropriate disposal method in your area.

In case of emergency/overdose

In case of an emergency or overdose with Imlygic, it is crucial to seek immediate medical attention. Contact your healthcare provider, local emergency services, or go to the nearest emergency room. It’s important to inform the medical professionals about the medication taken and the amount involved in the overdose for appropriate treatment.

What other information should I know?

Here are some additional points to be aware of:

• Administration: Imlygic is administered as an injection directly into the melanoma lesions in the skin or lymph nodes. It is usually given by a healthcare professional in a clinical setting.
• Side Effects: Imlygic may cause certain side effects, including flu-like symptoms such as chills, fever, fatigue, body aches, and headache. Other common side effects may include injection site reactions, nausea, and skin rash. Report any unusual or severe side effects to your healthcare provider.
• Precautions: Inform your healthcare provider about any existing medical conditions, including allergies and infections. Imlygic is a live virus-based therapy, so precautions should be taken to avoid transmission of the virus to others, particularly those who are immunocompromised.
• Interactions: It is important to disclose all medications, including prescription, over-the-counter drugs, and herbal supplements, to your healthcare provider. Some medications may interact with Imlygic, potentially affecting its effectiveness or increasing the risk of side effects.
• Pregnancy and Breastfeeding: The safety of Imlygic during pregnancy and breastfeeding has not been established. Consult your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding before using Imlygic.

Remember, this information is not exhaustive, and it’s always advisable to consult your healthcare provider or pharmacist for complete and personalized guidance on the storage, disposal, administration, and any other specific concerns related to Imlygic.